CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Wednesday reported a loss of $181.9 million in its first quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.73. Losses, adjusted for stock option expense, were $1.42 per share.
The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.84 per share.
The RNA interference drug developer posted revenue of $33.3 million in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $22 million.
Alnylam shares have increased 22% since the beginning of the year. The stock has declined roughly 6% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY